Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Xenetic Biosciences, Inc.

Get SEC filing alerts via email and in your feed for Xenetic Biosciences, Inc.

XBIO XBIOW

Xenetic Biosciences, Inc.

About Xenetic Biosciences, Inc.

Xenetic Biosciences is a biopharmaceutical company developing innovative immuno-oncology therapies, focusing on targeting tumor microenvironments with proprietary DNase technology. Its core activities include advancing drug candidates for solid tumors like pancreatic and colorectal cancers, leveraging collaborations and licensing. The company emphasizes research, strategic partnerships, and patent protection to create next-generation biologics addressing unmet medical needs in cancer treatment.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Xenetic Biosciences, Inc.

1
1
Xenetic Biosciences, Inc. Xenetic Biosciences Reports 36% Revenue Growth in Q1 2026, Net Loss Narrows

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Xenetic Biosciences, Inc. Xenetic Biosciences Reports Improved Financial Performance with Reduced Losses and Increased Revenue

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Xenetic Biosciences, Inc. Xenetic Biosciences Reports 67.2% Revenue Growth in Q3 2025, Net Loss Increases

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Xenetic Biosciences, Inc. Xenetic Biosciences Reports Decrease in Revenue and Continued Net Loss for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Xenetic Biosciences, Inc. Xenetic Biosciences Reports 16.1% Revenue Growth but Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Xenetic Biosciences, Inc. Xenetic Biosciences Reports Stable Revenue, Continued Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments